Related Experiment Video
Updated: Dec 6, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.1K
[Coagulopathy and COVID-19. Recommendations for a changing reality]
Dardo Riveros1, Daniela Maymó1, Julia Laviano1
1Servicio de Hematología, Medicina Transfusional y Trasplante de Médula ósea, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires, Argentina.
Medicina
|October 13, 2020
Summary
Critically ill COVID-19 patients face increased risks of blood clots and organ failure due to a hypercoagulable state. This study reviews evidence to recommend treatments for coagulopathy, aiming to reduce COVID-19 patient mortality.
Area of Science:
- Critical care medicine
- Hematology
- Infectious diseases
Background:
- Coronavirus disease 2019 (COVID-19) is associated with a significant risk of thromboembolic events.
- Critically ill patients with SARS-CoV-2 infection exhibit a hypercoagulable state, evidenced by elevated D-dimer levels.
- This hypercoagulability correlates with increased risks of organ failure and mortality.
Purpose of the Study:
- To analyze the scientific evidence regarding the therapeutic management of coagulopathy in COVID-19.
- To develop evidence-based recommendations for treating COVID-19-associated coagulopathy.
- To reduce patient morbidity and mortality through optimized therapeutic strategies.
Main Methods:
- Systematic review of available scientific literature.
- Analysis of hemostatic abnormalities in SARS-CoV-2 infected patients.
- Evidence synthesis for therapeutic decision-making.
Main Results:
- COVID-19 induces a hypercoagulable state with elevated D-dimer.
- Thromboembolism risk is elevated in critically ill COVID-19 patients.
- Hemostatic abnormalities are critical factors in patient outcomes.
Conclusions:
- Therapeutic decisions for COVID-19 patients must consider hemostasis abnormalities.
- Evidence-based recommendations are crucial for managing coagulopathy.
- Targeted interventions can potentially decrease COVID-19 morbidity and mortality.
Keywords:
COVID-19cytokine stormdisseminated intravascular coagulationheparinsepsis induced coagulopathythromboembolismMore Related Videos
Related Concept Videos
01:09Coagulation
9.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.1K
01:06Coagulation
914
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
914
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
01:24Disorders of Hemostasis
1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
01:29Venous Thrombosis III: Interprofessional Care
167
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
167
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K